
Commentary|Videos|April 8, 2024
The Inclisiran Impact on PCSK9: A Primary Care Primer
Author(s)Grace Halsey
ACC.24: Michael Koren, MD, highlights how the nonstatin lipid-lowering medication's mechanism of action against PCSK9 differs from others in the category.
Advertisement
Michael J Koren, MD, primary investigator of the VICTORION-INITIATE study of an "inclisiran first" strategy to reduce LDL-C in individuals with ASCVD, differentiates the small-interfering RNA molecule from other agents that reduce the impact of PCSK9 on the cardiovascular system.
Michael J Koren, MD, primary investigator of the VICTORION-INITIATE study, is a cardiologist and serves as the chief executive officer at ENCORE Research Group, in Jacksonville, FL. Koren founded ENCORE in 1997 and since then the organization has conducted more than 2500 clinical trials across 8 locations in Florida.
Newsletter
Enhance your clinical practice with the Patient Care newsletter, offering the latest evidence-based guidelines, diagnostic insights, and treatment strategies for primary care physicians.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Patient Care Online
1
First Oral Film Treatment for Erectile Dysfunction in Men Gains FDA Approval
2
Long-Term Data Support Sustained Bimekizumab Response in Hidradenitis Suppurativa
3
Weekly Dose Podcast: New Obesity Data, Insulin Guidance, and Mental Health Screening
4
Topline Phase 2 Data Show Roflumilast Cream Improves Atopic Dermatitis in Infants as Young as 3 Months
5



































































































































